Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

NCT07092514 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer
Cancer of the Thyroid

Interventions

DRUG: Lenvatinib

Sponsor

Washington University School of Medicine